Saturn V Capital Management LP
Saturn V Capital Management LP reported 23 holdings worth US$697M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Saturn V Capital Management LP reported 23 holdings worth US$697M as of Jun 30, 2026. Largest: Amylyx Pharmaceuticals, Inc., Alumis Inc. and Abivax Sa. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 23
- Value as reported
- US$697M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. | 4.62M | US$83M | 11.9% |
| Alumis Inc. | 2.92M | US$82M | 11.8% |
| Abivax Sa | 519K | US$69.1M | 9.9% |
| Vaxcyte, Inc. | 853K | US$49.6M | 7.1% |
| Immix Biopharma, Inc. | 4.66M | US$48M | 6.9% |
| Celcuity Inc. | 370K | US$38.7M | 5.6% |
| Disc Medicine, Inc. | 525K | US$38.4M | 5.5% |
| Candel Therapeutics, Inc. | 3.3M | US$34M | 4.9% |
| X4 Pharmaceuticals, Inc. | 6.97M | US$32.6M | 4.7% |
| Monopar Therapeutics Inc. | 312K | US$28.9M | 4.1% |
| Dyne Therapeutics, Inc. | 1.06M | US$23.5M | 3.4% |
| Trevi Therapeutics, Inc. | 1.05M | US$19.6M | 2.8% |
| Zura Bio Limited | 2.1M | US$12.4M | 1.8% |
| Sagimet Biosciences Inc. - Series A | 1.48M | US$11.4M | 1.6% |
| Inhibikase Therapeutics, Inc. | 3.87M | US$7.85M | 1.1% |
| Vir Biotechnology, Inc. | 771K | US$7.85M | 1.1% |
| Invivyd, Inc. | 8.39M | US$7.32M | 1.0% |
| Alto Neuroscience, Inc. | 183K | US$4.82M | 0.69% |
| Satellos Bioscience Inc | 350K | US$2.72M | 0.39% |
| Ovid Therapeutics Inc. | 663K | US$1.78M | 0.26% |
| Cogent Biosciences, Inc. | 0 | US$0 | 0.00% |